ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting


Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated ?9?2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors

Here is the original post:
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Related Posts